Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients

Fig. 2

Scheme of the HypoFocal-SBRT trial and examples of focal dose escalated SBRT and MHRT. The scheme shows the design of the experimental and control arm. Details of treatment plans for focal dose escalated stereotactic body radiotherapy (SBRT) (left) and moderate hypofractionation (MHRT) (right) are shown. SBRT was planned with a prescription dose of 42 Gy to the boost planning target volume (PTV) and 35 Gy to the PTV covering the prostate in 5 fractions. MHRT was planned with a prescription dose of 62 Gy to the PTV covering the prostate. Planning organ at risk (PRV) volume of urethra was considered for boost-PTV definition. This exemplary axial slide demonstrates the steep dose gradient in focal dose escalated SBRT and the conformal homogenous MHRT. Isodoses are illustrated according to the legend

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us